查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1837189

動物用藥品市場依產品類型、給藥途徑、動物類型及分銷管道分類－2025-2032年全球預測

Veterinary Drug Market by Product Category, Route Of Administration, Animal Type, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，動物用藥品市場規模將達到 393.7 億美元，年複合成長率為 6.16%。

關鍵市場統計數據
基準年 2024 243.9億美元
預計年份：2025年 259.1億美元
預測年份 2032 393.7億美元
複合年成長率 (%) 6.16%

針對不斷變化的動物治療環境，制定策略實施方案。重點闡述臨床、商業和監管方面的變化，這些變化要求產業做出果斷應對。

現代動物用藥品領域正處於技術創新加速、監管審查日益嚴格以及終端用戶期望不斷變化這三者交匯的十字路口。近年來，該行業見證了護理模式的演變，更加重視預防醫學、生物製藥以及更精細的抗菌藥物管理。這些動態正在再形成供應商和從業人員的行為，並促使他們在不同的治療層級和給藥方式之間重新平衡投資。

隨著相關人員不斷調整，清晰的策略基礎至關重要。獸醫和行業領導者正面臨著許多壓力，包括抗菌藥物使用監管日益嚴格、對更安全、更有針對性的治療方法的需求不斷成長，以及在不同動物種類和護理環境下提供醫療服務的實際情況。此外，數位化管道和遠端醫療的普及也開始影響產品的分銷方式以及飼主獲取治療方案的方式。因此，市場參與企業必須重新評估其產品組合的優先事項、生產能力以及與臨床終端使用者的互動模式，以保持競爭力。

從觀察到策略的轉變需要整合臨床趨勢和商業性現實。本導言概述了塑造該領域的關鍵力量，並為更深入的分析奠定了基礎，包括變革性轉變、關稅的影響、細分市場主導的機會、區域動態、競爭定位，以及為希望將洞見轉化為行動的領導者提供的實用建議。

具有重大影響的科學、監管和商業性變革正在改變動物治療的優先事項，並重新定義如何為臨床醫生和飼主提供價值。

動物用藥品領域的研發重點、製造地和商業模式正經歷著變革性的轉變。對生物製藥和新一代疫苗的關注，以及對抗菌藥物管理的重新重視，正促使研發人員致力於開發窄頻譜藥物、替代治療方法和更先進的診斷工具以指南治療。這些科學趨勢與營運轉型相呼應，建構更具韌性的供應鏈、靈活的生產模式以及採用合約開發和製造外包夥伴關係，正成為核心競爭力。

在商業性，通路動態正在不斷演變。傳統獸醫診所仍然是臨床干預的中心，而線上藥局和數位平台則擴大了服務覆蓋範圍。這種數位化，加上診療點數據收集的改進，為以結果為導向的產品和基於訂閱的預防性項目創造了機會。動物飼養方式的改變，包括對伴侶動物健康投入的增加，正在改變不同治療類別和給藥途徑的需求結構，進而影響處方決策和銷售策略。

法律規範和支付方的期望都在不斷變化，迫使企業制定能夠證明產品安全性、有效性和實際價值的循證方案。這些變化共同要求企業採取整合策略，將科學創新與供應鏈敏捷性和商業性現代化結合，以獲得永續優勢。

2025年的關稅壓力將促使企業進行全面的供應鏈重組、區域製造業轉移以及籌資策略調整，以保障市場進入和利潤空間。

2025年生效的關稅調整將為採購、定價和跨境物流帶來更多複雜性，影響產品供應和籌資策略。製造商和經銷商正在修訂供應商合約和運輸路線，以降低到岸成本上升並保護淨利率，同時確保產品供應。這些調整通常需要優先考慮短期庫存，並實現長期供應基礎多元化，以降低集中採購帶來的風險。

事實上，海關環境正在加速圍繞區域製造和回流生產的討論，尤其是在抗感染藥感染疾病和疫苗等關鍵投入品和成品方面。企業也正在重新審視轉讓定價框架和分銷協議，以控制跨區域成本。對於臨床相關人員而言，重新強調成本效益高、循證的治療方法選擇，將促使他們關注處方合理化和在可行的情況下治療方法替代。

展望未來，關稅很可能仍將是商業規劃中的一個結構性考慮因素，影響產能投資方向、優先考慮哪些合作夥伴關係以及如何建立分銷網路以平衡競爭性定價和韌性等決策。

深度細分觀點揭示了產品類型、給藥途徑、動物類型和分銷管道的交匯點，從而創造了差異化的商業機會。

精細的市場區隔方法揭示了治療需求和分銷複雜性的交匯點。依產品類型分析，市場包括感染疾病、抗發炎藥、抗寄生蟲藥和疫苗；感染疾病包括抗生素、抗真菌藥物和抗病毒藥；抗生素可進一步細分為頭孢菌素類、氟喹諾酮類、Fluoroquinolones、青黴素類和四環黴素。這種細緻的分類揭示了不同的創新路徑和管理考量，這些因素會影響研發重點和標籤策略。

給藥途徑也影響臨床應用和商業性物流，吸入劑、注射劑、口服劑和局部劑型各有不同的配方、儲存和給藥限制；水產養殖（包括魚蝦）的疾病特徵和給藥挑戰與伴侶動物（包括犬貓）不同；馬科動物醫學強調專門的治療方法和火雞給藥方案；

分銷管道進一步影響市場進入，線上藥局、實體藥局和獸醫診所各自擁有獨特的客戶接點和合規要求。整合這些細分市場有助於確定產品差異化、實證實踐和商業模式客製化在哪些方面能夠帶來最大的策略回報。

對美洲、歐洲、中東和非洲以及亞太地區的策略性洞察突顯了各地區在採納、監管和分銷需求方面的差異。

區域動態是製定有效商業和監管策略的核心。美洲市場的特點是擁有先進的獸醫臨床基礎設施、寵物飼養率高，以及對高階生技藥品和診斷產品的需求不斷成長。由於各地區的政策和支付模式各不相同，因此在市場准入和報銷談判方面需要採取細緻入微的方法。

歐洲、中東和非洲呈現出多元化的市場格局，部分市場面臨嚴格的監管環境，而有些市場則面臨新的准入挑戰。抗菌藥物管理框架和統一的安全標準在歐洲部分地區已較為完善，而畜牧業集約化程度提高和獸醫服務不斷擴展的市場則可能蘊藏著重要的成長機會。同時，該地區的供應鏈和進口法規將影響本地生產或分銷合作關係在哪些方面最為有利。

亞太地區的需求促進因素多元化，涵蓋了水產養殖業和大型畜牧業的蓬勃發展，以及城市中心伴侶動物照護的快速擴張。監管現代化、低溫運輸基礎設施投資以及日益成長的數位化正在重塑產品的商業化模式。這些區域性洞察表明，量身定做的監管策略、差異化的產品定位和靈活的分銷模式對於成功打入市場和永續成長至關重要。

競爭策略著重於整合療法、數位化服務、穩健的供應鏈和實證實踐，以在動物用藥品市場中脫穎而出。

隨著成熟的跨國動物用藥品公司不斷拓展產品組合，以及專注於生技藥品、診斷和新型抗寄生蟲藥物的靈活專業企業湧現，競爭格局正在不斷演變。領先企業優先考慮將治療藥物與數位化支援工具、療效追蹤和服務相結合的綜合解決方案，以增強獸醫和寵物飼主的參與度。策略合作和授權協議正被擴大用於加速新型治療方法的普及，並分散生技藥品和專科療法的研發風險。

無論涉及何種物種，投資於靈活生產、健全品質體系和彈性供應鏈的公司，都能更好地應對關稅波動和需求波動。同樣重要的是，它們能夠產生並傳播高品質的臨床證據，從而引起監管機構和臨床醫生的共鳴。隨著競爭格局的日趨成熟，那些將產品創新與便捷的交付方式和引人注目的提案主張相結合的公司，將在臨床偏好和採購決策方面獲得優勢。

領導者可以採取切實可行的策略行動，協調抗菌藥物管理、在地化生產和以通路為中心的商業化，以確保永續優勢。

產業領導者應優先採取一系列切實可行的措施，協調科學、供應和銷售，以抓住近期機會並建立長期韌性。首先，推動抗菌藥物管理舉措，同時進行標靶藥物和診斷方法的研發，有助於滿足不斷變化的監管要求和臨床醫生對更安全、循證治療的需求。其次，投資靈活的生產製造和區域生產能力，特別是針對關鍵生技藥品和疫苗，可以降低關稅和物流風險，並加快產品上市應對力。

在商業性，將治療藥物與數位化依從性工具和診所層面的支持相結合，可以加強與獸醫診所的聯繫，並使透過線上和線下藥局銷售的產品脫穎而出。細分市場策略應認知到，伴侶動物主人優先考慮便利性和先進的護理，而牲畜和家禽客戶則重視價格實惠、易於管理且擴充性。最後，企業領導者應採用靈活的定價和分銷模式，充分考慮當地的監管環境和通路經濟效益，以在維持臨床選擇的同時，保持競爭力。

採用嚴謹的混合調查方法，結合一手和二手研究以及情境分析，以檢驗趨勢和策略意義。

調查方法融合了量化和質化研究手段，旨在提供可靠且可操作的洞見。主要研究包括對價值鏈上的關鍵相關人員進行結構化訪談，訪談對象涵蓋臨床醫生、採購專家和行業高管，以了解他們對臨床需求、藥品目錄促進因素和分銷偏好的真實觀點。次要研究則依賴監管文件、臨床文獻、專利申請和企業資料披露資訊，以佐證研究趨勢並識別新興技術路徑。

此分析架構運用細分分析方法，從產品類型、給藥途徑、動物類型和分銷管道等方面入手，揭示需求模式和營運限制。情境分析用於壓力測試供應鏈和關稅敏感性，跨區域比較則揭示了監管和商業差異。數據品管和三角驗證技術用於檢驗分析結果，研究結果經過具有動物治療臨床和商業經驗的專家同行評審。

一項全面、前瞻性的研究，概述了科學、營運和商業性策略的整合將如何決定動物療法的長期成功。

總之，由於科學創新、監管環境的演變以及商業性促進因素的轉變，動物用藥品領域正經歷重大變革。積極實踐抗生素管理原則、投資於具有韌性和靈活性的生產製造，並商業性准入和擴大策略中。

最終，最成功的機構將是那些能夠將洞察轉化為協作執行的機構，它們將研發重點與切實可行的部署計劃相結合，建立加速新型治療方法普及的夥伴關係，並開發能夠引起從業人員和所有者共鳴的商業模式。臨床信譽、營運實力和商業性靈活性三者兼備，將決定在不斷發展的動物治療領域實現永續成功的道路。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 生物相似藥的日益普及可降低治療成本並擴大寵物用藥範圍
  • 加強抗菌藥物管理計劃，以應對畜牧生產中的抗生素抗藥性問題
  • 增加對創新口服給藥系統的投資，以提高寵物對藥物的接受度和依從性
  • 針對馬和牛族群中新出現的病毒性疾病的物種特異性mRNA疫苗的進展
  • 擴展的數位健康監測工具與藥物治療方案相結合，用於制定個人化的獸醫護理計劃

第6章美國關稅的累積影響，2025年

第7章 人工智慧的累積影響，2025年

第8章 按產品類型的動物用藥品市場

  • 抗感染藥物
    • 抗生素
      • 頭孢菌素
      • Fluoroquinolones
      • 大環內酯類
      • 青黴素
      • 四環黴素
    • 抗真菌藥物
    • 抗病毒藥物
  • 抗發炎藥
  • 殺寄生蟲劑
  • 疫苗

第9章 依給藥途徑分類的動物用藥品市場

  • 吸入
  • 注射
  • 口服
  • 局部的

第10章 依動物類型分類的動物用藥品市場

  • 水產養殖
    • 魚
    • 蝦
  • 伴侶動物
    • 狗
    • 貓科動物
  • 馬
  • 家畜
    • 牛
    • 小反芻動物
    • 豬
  • 家禽
    • 雞
    • 火雞

第11章 按分銷管道分類的動物用藥品市場

  • 網路藥房
  • 零售藥房
  • 獸醫診所

第12章 按地區分類的動物用藥品市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章動物用藥品市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國動物用藥品市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Zoetis Inc.
    • Elanco Animal Health Incorporated
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Ceva Sante Animale SA
    • Virbac SA
    • Phibro Animal Health Corporation
    • Dechra Pharmaceuticals PLC
    • Vetoquinol SA
    • Norbrook Laboratories Limited
Product Code: MRR-034B50030391

The Veterinary Drug Market is projected to grow by USD 39.37 billion at a CAGR of 6.16% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 24.39 billion
Estimated Year [2025] USD 25.91 billion
Forecast Year [2032] USD 39.37 billion
CAGR (%) 6.16%

A strategic introduction to the evolving veterinary therapeutics environment highlighting clinical, commercial, and regulatory forces that demand decisive industry responses

The contemporary veterinary drug landscape sits at the intersection of accelerating innovation, heightened regulatory scrutiny, and shifting end-user expectations. In recent years the industry has seen evolving modes of care that emphasize preventive health, biologics, and more nuanced antimicrobial stewardship. These dynamics are reshaping supplier and practitioner behavior, driving a rebalancing of investment across therapeutic classes and delivery formats.

As stakeholders adapt, the need for a clear strategic foundation becomes paramount. Veterinarians and industry leaders are navigating pressures from tighter regulations on antimicrobial use, rising demand for safer and more targeted therapies, and the operational realities of delivering care across diverse animal species and care settings. Moreover, the adoption of digital channels and telehealth has begun to influence how products are distributed and how owners access treatment options. Consequently, market participants must reassess portfolio priorities, manufacturing resilience, and engagement models with clinical end users to remain competitive.

Transitioning from observation to strategy requires synthesizing clinical trends with commercial realities. This introduction frames the essential forces shaping the field and sets the stage for deeper analysis on transformative shifts, tariff impacts, segmentation-driven opportunities, regional dynamics, competitive positioning, and practical recommendations for leaders seeking to translate insight into action.

High-impact scientific, regulatory, and commercial transformations are reshaping priorities in veterinary therapeutics and redefining how value is delivered to clinicians and owners

Transformative shifts are driving a reconfiguration of R&D priorities, manufacturing footprints, and commercial models within veterinary pharmaceuticals. The push toward biologics and next-generation vaccines has been accompanied by renewed attention to antimicrobial stewardship, prompting developers to pursue narrower-spectrum agents, alternative modalities, and enhanced diagnostic tools to guide therapy. These scientific trends are paralleled by operational transformations: supply chain resilience, flexible manufacturing, and the adoption of contract development and manufacturing partnerships are becoming core capabilities.

Commercially, channel dynamics are evolving as online pharmacies and digital platforms expand access while traditional veterinary hospitals remain central for clinical interventions. This digitization, combined with improved data capture at point of care, creates opportunities for outcomes-focused offerings and subscription-based preventative programs. Shifts in animal ownership patterns-such as higher investment in companion animal health-are altering demand mix across therapeutic categories and routes of administration, influencing formulary decisions and promotional strategies.

Regulatory frameworks and payer expectations are tightening, which compels companies to design evidence generation plans that demonstrate safety, efficacy, and real-world value. Collectively, these shifts require organizations to adopt integrated strategies that align scientific innovation with supply chain agility and commercial modernization to capture sustainable advantage.

Elevated tariff pressures in 2025 are prompting comprehensive supply chain redesigns, regional manufacturing shifts, and procurement strategies to safeguard access and margins

Tariff changes implemented in 2025 have introduced additional layers of complexity for sourcing, pricing, and cross-border logistics, affecting product availability and procurement strategies. Manufacturers and distributors are reassessing supplier contracts and transportation routes to mitigate increased landed costs and to preserve margins without compromising accessibility. These adjustments often necessitate near-term inventory prioritization and long-term supply base diversification to reduce exposure to concentrated sourcing risks.

In practice, the tariff environment has accelerated conversations around regional manufacturing and onshoring for critical inputs and finished products, particularly for essential classes such as anti-infectives and vaccines. Companies are also revisiting transfer pricing frameworks and distribution agreements to manage costs across geographies. For clinical stakeholders, the outcome is a heightened focus on formulary rationalization and therapeutic substitution where feasible, underpinned by a renewed emphasis on cost-effective, evidence-based therapy selection.

Looking ahead, tariffs are likely to remain a structural consideration in commercial planning, influencing decisions about where to invest in capacity, which partnerships to prioritize, and how to structure distribution networks to balance resilience with competitive pricing.

Deep segmentation perspectives reveal where product categories, administration routes, animal types, and distribution channels converge to create differentiated opportunities

A refined segmentation approach offers clarity on where therapeutic demand and distribution complexity converge. When analyzed by product category, the market encompasses anti-infectives, anti-inflammatories, parasiticides, and vaccines; within anti-infectives there are antibiotics, antifungals, and antivirals, and antibiotics can be further differentiated into cephalosporins, fluoroquinolones, macrolides, penicillins, and tetracyclines. This granularity reveals diverging innovation pathways and stewardship considerations that influence development priorities and labeling strategies.

Route of administration also shapes clinical adoption and commercial logistics, with inhalation, injectable, oral, and topical formats each presenting distinct formulation, storage, and administration constraints. Animal type segmentation shows differentiated demand drivers: aquaculture-comprising fish and shrimp-presents disease profiles and delivery challenges unlike those in companion animals, which include canines and felines; equine care emphasizes specialized therapeutics and dosing regimens; livestock, spanning cattle, small ruminants, and swine, requires scalable, cost-sensitive solutions; and poultry, represented by chickens and turkeys, demands approaches suited to mass administration and biosecurity.

Distribution channels further affect market access, where online pharmacies, retail pharmacies, and veterinary hospitals each offer unique customer touchpoints and compliance requirements. Synthesizing these segmentation lenses helps identify where product differentiation, targeted evidence, and tailored commercial models will deliver the greatest strategic return.

Regional strategic considerations across the Americas, Europe Middle East & Africa, and Asia-Pacific reveal differentiated adoption, regulatory, and distribution imperatives

Regional dynamics are central to effective commercial and regulatory strategy. In the Americas, markets are characterized by advanced veterinary clinical infrastructure, high companion animal ownership, and growing demand for premium biologics and diagnostics; these features support robust innovation and early adoption of novel therapeutics. Policies and payer models vary across the region, requiring nuanced approaches to market entry and reimbursement discussions.

Europe, Middle East & Africa present a heterogeneous landscape where stringent regulatory expectations in some markets coexist with emerging access challenges in others. Antimicrobial stewardship frameworks and harmonized safety standards are prominent in parts of Europe, while key growth opportunities may be found in markets with rising livestock intensity and expanding veterinary services. Meanwhile, supply chain considerations and import regulations in this region influence where localized manufacturing or distribution partnerships are most beneficial.

Asia-Pacific exhibits diverse demand drivers, from intensifying aquaculture production and large-scale livestock operations to rapidly expanding companion animal care in urban centers. Regulatory modernization, investments in cold chain infrastructure, and increasing digital adoption are reshaping how products are commercialized. Together, these regional insights suggest that tailored regulatory strategies, differentiated product positioning, and adaptive distribution models are essential for successful market penetration and sustainable growth.

Competitive strategies are coalescing around integrated therapeutics, digital services, resilient supply chains, and evidence generation to outpace peers in veterinary markets

Competitive positioning is evolving as incumbent multinational animal health companies expand their portfolios alongside nimble specialized players focused on biologics, diagnostics, and novel antiparasitic agents. Leading firms are prioritizing integrated solutions that combine therapeutics with digital support tools, outcomes tracking, and services that enhance veterinarian and owner engagement. Strategic collaborations and licensing agreements are increasingly used to accelerate access to novel modalities and to spread the development risk associated with biologics and specialty therapeutics.

Operational excellence remains a differentiator: companies that have invested in flexible manufacturing, robust quality systems, and resilient supply chains are better positioned to navigate tariff volatility and fluctuating demand across animal types. Equally important is the ability to generate and communicate high-quality clinical evidence that resonates with both regulatory bodies and practitioners. As the competitive landscape matures, firms that align product innovation with accessible delivery formats and compelling value propositions will secure advantage in both clinical preference and procurement decisions.

Practical strategic actions for leadership to synchronize antimicrobial stewardship, regional manufacturing, and channel-focused commercialization for sustained advantage

Industry leaders should prioritize a set of actionable moves that align science, supply, and sales to capture near-term opportunities while building long-term resilience. First, advancing antimicrobial stewardship initiatives alongside development of targeted agents and diagnostics will meet evolving regulatory expectations and clinician demand for safer, evidence-based therapies. Second, investing in flexible manufacturing and regional capacity-especially for critical biologics and vaccines-will mitigate tariff and logistics exposure and accelerate market responsiveness.

Commercially, tailoring offerings by combining therapeutics with digital adherence tools and practice-level support will strengthen relationships with veterinary hospitals and differentiate products sold through online and retail pharmacies. Segment-focused strategies should recognize that companion animal owners prioritize convenience and advanced care, whereas livestock and poultry customers emphasize affordability, ease of administration, and scalability. Finally, leaders should adopt agile pricing and distribution models informed by regional regulatory landscapes and local channel economics to maintain competitiveness while preserving clinical choice.

A rigorous mixed-methods research approach combining primary stakeholder interviews, secondary intelligence, and scenario analysis to validate trends and strategic implications

The research methodology blends quantitative and qualitative approaches to ensure robust, actionable findings. Primary research involved structured interviews with key stakeholders across the value chain, including clinical practitioners, procurement specialists, and industry executives, to capture real-world perspectives on clinical needs, formulary drivers, and distribution preferences. Secondary research incorporated regulatory documents, clinical literature, patent filings, and company disclosures to corroborate trends and identify emerging technology pathways.

Analytical frameworks applied include segmentation analysis across product categories, routes of administration, animal types, and distribution channels to reveal demand patterns and operational constraints. Scenario analysis was used to stress-test supply chain and tariff sensitivities, while cross-regional comparisons illuminated regulatory and commercial variances. Data quality controls and triangulation methods were employed throughout to validate insights, and findings were peer-reviewed by subject matter experts with clinical and commercial experience in veterinary therapeutics.

A forward-looking synthesis outlining how integrated scientific, operational, and commercial strategies will determine long-term success in veterinary therapeutics

In conclusion, the veterinary drug landscape is undergoing a period of substantive change driven by scientific innovation, regulatory evolution, and shifting commercial dynamics. Stakeholders who proactively integrate antimicrobial stewardship principles, invest in resilient and flexible manufacturing, and tailor commercial approaches to the unique needs of each animal segment and distribution channel will be best positioned to capture long-term value. Regional nuance remains a decisive factor: the Americas, Europe Middle East & Africa, and Asia-Pacific each present distinct regulatory, clinical, and logistical realities that must inform market entry and expansion strategies.

Ultimately, the most successful organizations will be those that translate insight into coordinated execution-aligning R&D priorities with practical deployment plans, building partnerships that accelerate access to novel modalities, and deploying commercial models that resonate with practitioners and owners. This synthesis of clinical credibility, operational strength, and commercial agility defines the pathway to sustainable success in the evolving veterinary therapeutics arena.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of biosimilar therapeutics to reduce treatment costs and expand access for companion animals
  • 5.2. Increased focus on antimicrobial stewardship programs to combat antibiotic resistance in livestock production
  • 5.3. Rising investment in innovative oral delivery systems enhancing palatability and compliance in pet medications
  • 5.4. Advancements in species-specific mRNA vaccines targeting emerging viral diseases in equine and bovine populations
  • 5.5. Expansion of digital health monitoring tools integrated with drug regimens for personalized veterinary care plans

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Veterinary Drug Market, by Product Category

  • 8.1. Anti-Infectives
    • 8.1.1. Antibiotics
      • 8.1.1.1. Cephalosporins
      • 8.1.1.2. Fluoroquinolones
      • 8.1.1.3. Macrolides
      • 8.1.1.4. Penicillins
      • 8.1.1.5. Tetracyclines
    • 8.1.2. Antifungals
    • 8.1.3. Antivirals
  • 8.2. Anti-Inflammatories
  • 8.3. Parasiticides
  • 8.4. Vaccines

9. Veterinary Drug Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Injectable
  • 9.3. Oral
  • 9.4. Topical

10. Veterinary Drug Market, by Animal Type

  • 10.1. Aquaculture
    • 10.1.1. Fish
    • 10.1.2. Shrimp
  • 10.2. Companion Animals
    • 10.2.1. Canines
    • 10.2.2. Felines
  • 10.3. Equine
  • 10.4. Livestock
    • 10.4.1. Cattle
    • 10.4.2. Small Ruminants
    • 10.4.3. Swine
  • 10.5. Poultry
    • 10.5.1. Chickens
    • 10.5.2. Turkeys

11. Veterinary Drug Market, by Distribution Channel

  • 11.1. Online Pharmacies
  • 11.2. Retail Pharmacies
  • 11.3. Veterinary Hospitals

12. Veterinary Drug Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Veterinary Drug Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Veterinary Drug Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Zoetis Inc.
    • 15.3.2. Elanco Animal Health Incorporated
    • 15.3.3. Merck & Co., Inc.
    • 15.3.4. Boehringer Ingelheim International GmbH
    • 15.3.5. Ceva Sante Animale S.A.
    • 15.3.6. Virbac S.A.
    • 15.3.7. Phibro Animal Health Corporation
    • 15.3.8. Dechra Pharmaceuticals PLC
    • 15.3.9. Vetoquinol S.A.
    • 15.3.10. Norbrook Laboratories Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL VETERINARY DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL VETERINARY DRUG MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL VETERINARY DRUG MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. VETERINARY DRUG MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. VETERINARY DRUG MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. VETERINARY DRUG MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL VETERINARY DRUG MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL VETERINARY DRUG MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL VETERINARY DRUG MARKET SIZE, BY CEPHALOSPORINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL VETERINARY DRUG MARKET SIZE, BY FLUOROQUINOLONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL VETERINARY DRUG MARKET SIZE, BY MACROLIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL VETERINARY DRUG MARKET SIZE, BY PENICILLINS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL VETERINARY DRUG MARKET SIZE, BY TETRACYCLINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIFUNGALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTIVIRALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANTI-INFLAMMATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL VETERINARY DRUG MARKET SIZE, BY PARASITICIDES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL VETERINARY DRUG MARKET SIZE, BY VACCINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL VETERINARY DRUG MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL VETERINARY DRUG MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL VETERINARY DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL VETERINARY DRUG MARKET SIZE, BY TOPICAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL VETERINARY DRUG MARKET SIZE, BY FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL VETERINARY DRUG MARKET SIZE, BY SHRIMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL VETERINARY DRUG MARKET SIZE, BY CANINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL VETERINARY DRUG MARKET SIZE, BY FELINES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL VETERINARY DRUG MARKET SIZE, BY EQUINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL VETERINARY DRUG MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL VETERINARY DRUG MARKET SIZE, BY SMALL RUMINANTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL VETERINARY DRUG MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL VETERINARY DRUG MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL VETERINARY DRUG MARKET SIZE, BY CHICKENS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL VETERINARY DRUG MARKET SIZE, BY TURKEYS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL VETERINARY DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL VETERINARY DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL VETERINARY DRUG MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL VETERINARY DRUG MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL VETERINARY DRUG MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 235. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. AMERICAS VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 237. AMERICAS VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 238. AMERICAS VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 239. AMERICAS VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 240. AMERICAS VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 241. AMERICAS VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 242. AMERICAS VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 243. AMERICAS VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2024 (USD MILLION)
  • TABLE 244. AMERICAS VETERINARY DRUG MARKET SIZE, BY POULTRY, 2025-2032 (USD MILLION)
  • TABLE 245. AMERICAS VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 246. AMERICAS VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 257. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 260. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 261. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 262. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 263. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 264. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 265. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2024 (USD MILLION)
  • TABLE 266. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2025-2032 (USD MILLION)
  • TABLE 267. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 268. NORTH AMERICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 279. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 282. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 283. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 284. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 285. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 286. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 287. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2024 (USD MILLION)
  • TABLE 288. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2025-2032 (USD MILLION)
  • TABLE 289. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 290. LATIN AMERICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY POULTRY, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE, MIDDLE EAST & AFRICA VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 322. EUROPE VETERINARY DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 323. EUROPE VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. EUROPE VETERINARY DRUG MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. EUROPE VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 326. EUROPE VETERINARY DRUG MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 327. EUROPE VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 328. EUROPE VETERINARY DRUG MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 329. EUROPE VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 330. EUROPE VETERINARY DRUG MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 331. EUROPE VETERINARY DRUG MARKET SIZE, BY POULTRY, 2018-2024 (USD MILLION)
  • TABLE 332. EUROPE VETERINARY DRUG MARKET SIZE, BY POULTRY, 2025-2032 (USD MILLION)
  • TABLE 333. EUROPE VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 334. EUROPE VETERINARY DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 335. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 336. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 337. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2018-2024 (USD MILLION)
  • TABLE 338. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY PRODUCT CATEGORY, 2025-2032 (USD MILLION)
  • TABLE 339. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2018-2024 (USD MILLION)
  • TABLE 340. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY ANTI-INFECTIVES, 2025-2032 (USD MILLION)
  • TABLE 341. MIDDLE EAST VETERINARY DRUG MARKET SIZE, BY ANTIBIOTICS, 2018-2024 (USD M